Aduro Biotech's Preclinical Results for Its STING-Targeted

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aduro Biotech's Preclinical Results for Its STING-Targeted CDN Immuno-Oncology Platform Highlighted in Prestigious Peer-Reviewed Publications

BERKELEY, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ) today announced two publications in prestigious peer-reviewed journals highlighting the anti-tumor activity of its synthetic cyclic dinucleotide (CDN) molecules when used to treat aggressive metastatic cancers in preclinical models. The journal articles in Cell Reports and in Science and Translational Medicine showcase the ability of Aduro's CDN molecules to specifically target the human STING pathway, which when activated, have been shown to initiate broad innate immune responses that lead to effective and specific adaptive immune responses.

"Having our data peer-reviewed and featured in these major journals is a tremendous validation of our CDN technology and approach to activating the novel STING receptor," said Thomas W. Dubensky, Jr., Ph.D., chief scientific officer for Aduro. "In preclinical animal models, our synthetic CDN molecules potently activate immune stimulating cells including dendritic cells through this central pathway, altering the tumor microenvironment which leads to induction of tumor-specific T cells, durable immune-mediated tumor shrinkage and immune protection when re-challenged with the same tumor cells. In addition, we have shown that our synthetic CDN molecules activate all known variants of human STING receptors. Our ultimate goal with ADU-S100 and other novel CDN candidates is to design compounds that offer an off-the-shelf therapeutic approach to stimulate personalized responses to fight each patient's specific cancer."

The publication, entitled "Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity," is available online in Cell Reports, with the full article available at http://cellreports.cell.com . The researchers demonstrated that injecting tumors with ADU-S100 induced profound regression of established melanoma, colon cancer and breast cancer tumors in mice, both in the injected tumors and distal, untreated lesions. Importantly, treatment of a single tumor initiated a systemically effective T cell response that prevented outgrowth of untreated tumors in other areas of the body (metastases). The ADU-S100-initiated response was durable, and provided long-lived immunologic memory and lasting anti-tumor protection.

"Using CDNs to target STING is a unique approach and recent discovery in the immuno-oncology field," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "As announced in March, we are working with Novartis to advance STING-targeted therapies for oncology to use this very powerful mechanism to unlock and activate the immune system to seek and destroy tumor cells in patients."

A second peer-reviewed journal article on Aduro's CDN molecules, entitled "STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade," was published on April 15, 2015 in Science and Translational Medicine , available here . The data demonstrate that the increased anti-tumor activity of GVAX cancer vaccines formulated with Aduro's CDN molecules was STING-dependent and correlated with increased activation of dendritic cells and antigen-specific CD8 + T cells. In addition, tumors in treated mice showed significant up-regulation of PD-L1. Further, the data showed that the combination therapy of CDN molecules formulated with GVAX cancer vaccines and antibodies blocking the PD-1 immune checkpoint induced significant regression or elimination of established tumors which had not responded to treatment with anti-PD-1 inhibitors alone.

On March 30, 2015, Aduro and Novartis announced a major collaboration to develop the CDN platform targeting the STING pathway for oncology. Under the terms of the agreement, Novartis made an upfront payment of $200 million to Aduro and has committed to paying up to an additional $500 million in development milestones. In addition, Novartis invested $50 million in equity in Aduro. Aduro will lead commercialization activities and will book sales in the U.S., with Novartis leading commercialization in all other regions. The companies will share in profits in the U.S., Japan and major European countries. Novartis will pay Aduro a double digit royalty for sales in the rest of the world.

About Cyclic Dinucleotide (CDN)

Aduro's proprietary CDN product candidates are synthetic small molecule immune modulators that are designed to target and activate a receptor known as the Stimulator of Interferon Genes, or STING. The STING receptor is generally expressed at high levels in immune cells, including dendritic cells. Once activated, the STING receptor initiates a profound innate immune response through multiple pathways, inducing the expression of a broad profile of cytokines, including interferons and chemokines. This subsequently leads to the development of an effective tumor antigen-specific T cell adaptive immune response. 

About Aduro

Aduro Biotech, Inc. is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro's lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using cyclic dinucleotide (CDN) synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.aduro.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology, plans and timing of our clinical trials and the potential for eventual regulatory approval of our product candidates. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do,       our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in the final prospectus from our initial public offering which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 138

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 84

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 162

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 49

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 195

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 103

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 104

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Why Investors Are Making Bold Moves with Dell Technologies

Updated Category News Views 178

Investors Show Confidence in Dell Technologies In recent trading sessions, significant investors have adopted a bullish approach to Dell Technologies (NYSE: DELL). Such movements usually signal investor confidence and the possibility of future price movements. Interestingly, options trading data we've analyzed indicates that this activity stemmed from large transactions,...

Continue Reading
Community Heritage Financial Strengthens Capital Position with Debt Offering

Updated Category News Views 78

Community Heritage Financial Completes Subordinated Debt Offering Community Heritage Financial, Inc. (OTC PK: CMHF), parent company of Middletown Valley Bank, has successfully executed a private placement of subordinated debt, amounting to a substantial $12.1 million. This offering of 6.75% Fixed-to-Floating Rate Subordinated Notes, due 2034, reflects the Company’s...

Continue Reading
Evolent Health Poised for Growth Amid Humana Challenges

Updated Category News Views 185

Understanding Evolent Health's Market Position Recently, analysts at Barclays have reaffirmed their positive outlook on Evolent Health (NYSE: EVH), maintaining an Overweight rating and a price target of $39.00. This confidence comes in light of discussions surrounding the impacts of Humana's recent struggles with Medicare Star ratings. The management team at Evolent,...

Continue Reading
Caracole Teams with Centric PLM for Seamless Growth

Updated Category News Views 31

Revolutionizing the Luxury Furniture Game In the world of luxury furnishings, where every curve and finish sends a message, Caracole is making a bold move to streamline its operations. They're throwing the confetti for Centric PLM, a platform that's set to oust the scattered chaos of spreadsheets and emails. And let me tell you, for any investor eyeing the luxury home...

Continue Reading
RaySearch Laboratories: Exciting Year-End Presentation Ahead

Updated Category News Views 105

Join Us for RaySearch Laboratories' Year-End Report Presentation Analysts, investors, and media representatives are cordially invited to a detailed presentation focused on RaySearch Laboratories' Year-end report for the year 2024. Details of the Presentation Set for February 21, 2025, at 10:00 AM CET, the report will be made accessible to attendees starting at 07:45 AM on...

Continue Reading